InvestmentJul 24, 2026, 07:16 AM
Radiopharm Theranostics Raises US$8.8M in Combined Offerings
AI Summary
Radiopharm Theranostics Limited announced a capital raise totaling approximately US$8.8 million through a combination of offerings. This includes a US registered direct offering of American Depositary Shares (ADSs) and concurrent private placement of warrants, raising US$4.1 million. Additionally, the company secured A$6.7 million (US$4.7 million) from an Australian private placement and plans a Share Purchase Plan for up to A$6 million (US$4.2 million). The proceeds are intended to fund the RAD101 registrational study, progress therapeutic programs, and for general corporate purposes.
Key Highlights
- Radiopharm Theranostics raised US$4.1 million from a registered direct offering of 1,281,646 ADSs at US$3.16 per ADS.
- A concurrent private placement issued warrants to purchase 1,281,646 ADSs at an exercise price of US$3.79 per ADS, expiring July 31, 2029.
- An Australian private placement secured A$6.7 million (US$4.7 million) from institutional and professional investors.
- A Share Purchase Plan will be offered to Australian and New Zealand shareholders to raise up to an additional A$6 million (US$4.2 million).
- Funds will support the RAD101 registrational study, advance therapeutic programs, and for general corporate purposes.
- Shareholder approval is required for certain issuances and options, with an EGM expected around September 11, 2026.
Price Impact
More from RADX